ASH: Better Safety Could Boost BMS’s Anti-GPRC5D CAR-T

 
• By Alaric DeArment
  
Bristol Myers Squibb at ASH 2024 (Alaric DeArment/Scrip)

More from Cell Therapies

More from Conferences